Chronic Subdural Hematoma Clinical Trial
Official title:
Bedside Versus Operating Room Burr-Hole Drainage of Chronic Subdural Hematoma (DECIDE)
DECIDE (Bedside versus Operating Room Burr-Hole DrainagE of ChronIc SubDural HEmatoma)
CSDH is an abnormal collection of blood between the layers of the brain causing brain tissue
compression leading to neurological complications. One of the most common risk factors
contributing to CSDH is head trauma, which is usually in the form of a minor head injury.
Older individuals are at increased risk of CSDH due to brain atrophy that occurs with
advancing age as well as their tendency to fall and sustain minor head traumas. Chronic
alcoholics are also at increased risk as alcoholism also leads to brain atrophy, increased
risk of falls, and liver failure which results in increased bleeding risk. Also many drugs
used today like anticoagulants, antithrombotics, and antiplatelets for certain health
conditions are other common risk factors for CSDH.
The overall goal of this multi-centered trial in the USA and Canada is to assess the
surgical management of chronic subdural hematoma (CSDH) and to demonstrate the effectiveness
of bedside drainage and its safety as it bypasses the perioperative risk associated with
anesthetic especially among the elderly.
Adult patients with a clear indication for CSDH drainage will be randomly assigned to one of
two procedures. One group will receive the twist drill procedure which can be performed at
the bedside. The second group will undergo the burr-hole drainage procedure in the operating
room usually under general anesthetic. Typically, the twist drill procedure can occur sooner
as the operating room and Anesthetist are not required. Reoccurrence of the CSDH will be
assessed over a period of 6 months following drainage. Timing of procedure, risk of
infection, adverse side effects and neurological functioning will also be measured.
Over a 3 year study period, 486 eligible patients (243 patients per arm) will be enrolled.
Patients > 18 years with confirmed diagnosis of symptomatic CSDH will be provided one of the
two procedures and will be followed for study outcomes at 1, 3 and 6 months following the
procedure.
Primary analysis will be to compare the surgical procedures, assessing the recurrence rate
of CSDH within 6 months of initial CSDH drainage.
The ultimate goal of this study is to standardize bedside drainage as the treatment of
choice for CSDH management.
This trial is important in the ongoing search for more efficient and safe intervention
strategies.
DECIDE (Bedside versus Operating Room Burr-Hole DrainagE of ChronIc SubDural HEmatoma)
Background and Significance: Chronic subdural hematoma (CSDH) is an abnormal collection of
liquefied blood products between the dura and arachnoid membranes of the brain that may
cause brain tissue compression and subsequent neurological sequelae. One of the most common
risk factors contributing to CSDH is head trauma, which is usually in the form of a minor
head injury. Older individuals are at increased risk of CSDH due to brain atrophy that
occurs with advancing age as well as their tendency to fall and sustain minor head traumas.
Chronic alcoholics are also at increased risk as alcoholism leads to globalized brain
atrophy, increased risk of falls, and hepatogenic coagulopathy. Coagulopathies including the
use of anticoagulants, antithrombotics, and antiplatelets for certain health conditions are
other common risk factors for CSDH.
Study Aims: The primary aim of our study is to conduct a high-quality randomized trial to
compare the safety and effectiveness of the bedside and operating room burr-hole drainage of
CSDH. The main objective of this study is to demonstrate the effectiveness of bedside
drainage and its safety as it bypasses the perioperative risk associated with anesthetic
especially among the elderly.
The ultimate goal of this study is to standardize bedside drainage as the treatment of
choice for CSDH management.
Primary Objective: To assess the efficacy of bedside drainage compared to operating room
burr-hole evacuation for CSDH management by examining the hypothesis that bedside is
associated with lower recurrence rate.
Secondary Objectives: To examine if the bedside drainage and the operating room burr-hole
drainage are efficacious in terms of functional outcomes. To evaluate the hypothesis that
bedside drainage is safer compared to the operating room burr-hole drainage by measuring
mortality and morbidity.
Overall study design: Multi-centered pragmatic randomized controlled trial across North
America (USA and Canada) comparing bedside drainage with operating room burr-hole drainage
of CSDH.
Duration: Over a 3 year study period, each patient will be followed for 6 months to measure
the study outcomes.
Study population: The study population will include 486 eligible patients >18 years of age
with confirmed diagnosis of symptomatic CSDH (243 patients per arm).
Inclusion Criteria: Patients aged > 18 years presenting with symptomatic CSDH confirmed on
diagnostic imaging, who are able to provide informed consent or have a legal representatives
available if unable to do so.
Main intervention and comparator(s): Patients will be randomly assigned between the two arms
of the study, bedside and operating room burr-hole drainage. For patients randomized to
bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's
bedside using local anesthetic. For patients randomized to burr-hole drainage, the procedure
will be performed in the operating room under local or general anesthesia based on the
surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
Randomization via www.randomize.net website will be stratified by center and by patient age
in variable unspecified block sizes.
Follow-Up Post-Randomization: Patients randomized will be followed for study outcomes on
days 1, 2, discharge, and months 1, 3 and 6.
Primary Outcome: The efficacy of comparative surgical procedures will be measured by the
recurrence rate of CSDH within 6 months of initial CSDH drainage.
Secondary Functional Outcomes: Postoperative neurological and functional status of the
patients will be measured using the Markwalder Grading System (MGS), Glasgow Outcome Score
(GOS), and modified Rankin Scale (MRS).
Secondary Safety Outcomes: The safety of both procedures will be measured in terms of
mortality and morbidity including surgical site infections, misplacement of postoperative
subdural drain, tension pneumocephalus, new intracranial hemorrhage, and other medical
complications.
Sample Size: Sample size estimation is based on a Chi-squared two-sided test of the null
hypothesis that bedside drainage is not different from burr-hole drainage in reducing the
proportion of patients who experience a hematoma recurrence within 6 months of the drainage
procedure. Including for possible attrition rate of 10% a total of 486 patients (243 per
arm) will be required to detect a difference in recurrence rates of 7% or a risk ratio of
0.36 (11% in the burr-hole group and 4% in the bedside drainage group), with a power of 80%
and a level of significance set at alpha=0.05.
Primary Analysis: Primary analysis will be by intention-to-treat and data analyst will be
blinded to participant allocation.
Interim Analyses: Interim analyses will be conducted upon recruitment of 25% of the expected
sample size (122 patients) to assess recruitment rates, recurrence rates and safety
outcomes.
This trial is important in the ongoing search for more efficient and safe intervention
strategies.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06347796 -
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
|
N/A | |
Recruiting |
NCT04065113 -
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT02938468 -
Mgt of Chronic Subdural Hematoma Using Dexamethasone
|
Phase 2/Phase 3 | |
Completed |
NCT03307395 -
Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma
|
N/A | |
Terminated |
NCT04502745 -
A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation
|
N/A | |
Terminated |
NCT03353259 -
Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery
|
Phase 2/Phase 3 | |
Recruiting |
NCT02568124 -
Tranexamic Acid in Chronic Subdural Hematomas
|
Phase 2/Phase 3 | |
Completed |
NCT02282228 -
Detecting Chronic Subdural Hematoma With Microwave Technology
|
N/A | |
Recruiting |
NCT05143216 -
High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study
|
||
Active, not recruiting |
NCT04816591 -
Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
|
N/A | |
Recruiting |
NCT06401772 -
The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma
|
N/A | |
Completed |
NCT06134206 -
Burr Hole Ultrasound Study
|
N/A | |
Recruiting |
NCT03666949 -
General Anesthesia Versus Locoregional Anesthesia for Evacuation of Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT03280212 -
Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma
|
Phase 3 | |
Completed |
NCT03447327 -
Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT05374681 -
Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization
|
N/A | |
Recruiting |
NCT05267184 -
Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma
|
N/A | |
Not yet recruiting |
NCT05900557 -
Neurologic Deficits and Recovery in Chronic Subdural Hematoma
|
N/A | |
Completed |
NCT02757235 -
The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma
|
N/A | |
Terminated |
NCT02111785 -
Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma
|
Phase 2/Phase 3 |